Shooting the messenger: Targeting signal transduction pathways in leukemia and related disorders

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 1, 2011, Pages 33-44

  Noor, Suzita M ^a,b   Bell, Richard ^c   Ward, Alister C ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c Andrew Love Cancer Centre   (Australia)

Author keywords

BCR ABL; HDAC; JAK2; Leukemia; Myeloproliferative disorders; PI 3 kinase; Signaling pathways; STAT5; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CORE BINDING FACTOR BETA; CYTOKINE RECEPTOR; ERYTHROPOIETIN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; INTERLEUKIN 3; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; LESTAURTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NILOTINIB; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; UNINDEXED DRUG; WP 1066;

ACUTE LYMPHOBLASTIC LEUKEMIA; CAUSAL ATTRIBUTION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; LEUKEMIA; METHYLATION; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

EID: 79952361856     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.05.002     Document Type: Review

References (179)

1. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142.
2. Benekli M., Baer M.R., Baumann H., Wetzler M. Signal transducer and activator of transcription proteins in leukemia. Blood 2003, 101:2940-2954.
3. Jordan C.T. Searching for leukemia stem cells-not yet the end of the road?. Cancer Cell 2006, 10:253-254.
4. LLS. Leukemia and Lymphoma Society: Leukemia, lymphoma, myeloma facts: 2009-2010; 2009.
5. Gilliland D.G. Targeted therapies in myeloid leukemias. Ann Hematol 2004, 83(Suppl. 1):S75-S76.
6. Look A.T. Molecular pathogenesis of MDS. Hematol Am Soc Hematol Educ Program 2005, 156-160.
7. Winick N.J., Carroll W.L., Hunger S.P. Childhood leukemia-new advances and challenges. N Engl J Med 2004, 351:601-603.
8. Bhojwani D., Moskowitz N., Raetz E.A., Carroll W.L. Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia. Paediatr Drugs 2007, 9:149-156.
9. Quintas-Cardama A., Cortes J. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res 2008, 32:1313-1316.
10. Mauro M.J. Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer Control 2009, 16:108-121.
11. Tefferi A. Is "cure" essential in the treatment of cancer?. Mayo Clin Proc 2008, 83:1413-1414.
12. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008, 22:3-13.
13. Hehlmann R., Berger U., Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 2005, 84:487-497.
14. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
15. Landolfi R., Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 2008, 93:331-335.
16. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953.
17. Gokbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2006, 133-141.
18. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
19. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Am J Health Syst Pharm 2007, 64:S9-S15.
20. Ishaqi M.K., Afzal S., Dupuis A., et al. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 2008, 41:245-252.
21. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
22. Huang X.J., Liu D.H., Liu K.Y., et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 92:414-417.
23. Petzer A.L., Gunsilius E. Hematopoietic stem cells in chronic myeloid leukemia. Arch Med Res 2003, 34:496-506.
24. Devetten M., Armitage J.O. Hematopoietic cell transplantation: progress and obstacles. Ann Oncol 2007, 18:1450-1456.
25. Finazzi G., Barbui T. The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med 2007, 2:13-18.
26. Ricksten A., Palmqvist L., Johansson P., Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008, 93:1260-1261.
27. Spanoudakis E., Bazdiara I., Kotsianidis I., et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Ann Hematol 2009, 88:629-632.
28. Landolfi R., Di Gennaro L., Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008, 22:2020-2028.
29. Lengfelder E., Griesshammer M., Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996, 22(Suppl. 1):135-142.
30. Jurado M., Deeg H., Gooley T., et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol 2001, 112:392-396.
31. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008, 8:533-544.
32. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., et al. c-FMS mutational analysis in acute myeloid leukaemia. Br J Haematol 2003, 123:749-750.
33. Dewar A.L., Cambareri A.C., Zannettino A.C., et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005, 105:3127-3132.
34. Parcells B.W., Ikeda A.K., Simms-Waldrip T., et al. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 2006, 24:1174-1184.
35. Gilliland D.G. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002, 39:6-11.
36. Ravandi F., Jilani I., Estey E., et al. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res 2007, 31:791-797.
37. Kent D., Copley M., Benz C., et al. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin Cancer Res 2008, 14:1926-1930.
38. Escribano L., Ocqueteau M., Almeida J., et al. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma 1998, 30:459-466.
39. Ikeda H., Kanakura Y., Tamaki T., et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991, 78:2962-2968.
40. Beghini A., Peterlongo P., Ripamonti C.B., et al. C-kit mutations in core binding factor leukemias. Blood 2000, 95:726-727.
41. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
42. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312.
43. Schwertfeger K.L. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009, 10:632-644.
44. Golub T.R., Barker G.F., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5:12) chromosomal translocation. Cell 1994, 77:307-316.
45. Tefferi A., Gilliland G. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol 2006, 19:365-385.
46. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
47. Heath C., Cross N.C. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. J Biol Chem 2004, 279:6666-6673.
48. Fishley B., Alexander W.S. Thrombopoietin signalling in physiology and disease. Growth Factors 2004, 22:151-155.
49. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.
50. Wojchowski D.M., Menon M.P., Sathyanarayana P., et al. Erythropoietin-dependent erythropoiesis: new insights and questions. Blood Cells Mol Dis 2006, 36:232-238.
51. De la Chapelle A., Träskelin A.L., Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci USA 1993, 90:4495-4499.
52. Liongue C., Wright C., Russell A.P., Ward A.C. Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int J Biochem Cell Biol 2009, 41:2372-2375.
53. Testa U., Riccioni R., Diverio D., et al. Interleukin-3 receptor in acute leukemia. Leukemia 2004, 18:219-226.
54. Wolfler A., Erkeland S.J., Bodner C., et al. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood 2005, 105:3731-3736.
55. Gits J., van Leeuwen D., Carroll H.P., et al. Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. Leukemia 2006, 20:2111-2118.
56. Ward A.C. The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci 2007, 12:608-618.
57. Gale R.E., Freeburn R.W., Khwaja A., et al. A truncated isoform of the human beta chain common to the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 with increased mRNA expression in some patients with acute leukemia. Blood 1998, 91:54-63.
58. O'Sullivan L.A., Liongue C., Lewis R.S., et al. Cytokine receptor signaling through the Jak/Stat/Socs pathway in disease. Mol Immunol 2007, 44:2497-2506.
59. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
60. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
61. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
62. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
63. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209.
64. Hookham M.B., Elliott J., Suessmuth Y., et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007, 109:4924-4929.
65. Morgan K.J., Gilliland D.G. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008, 59:213-222.
66. Shide K., Shimoda H.K., Kumano T., et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008, 22:87-95.
67. Ma A.C., Fan A., Ward A.C., et al. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera. Exp Hematol 2009, 37:1379-1386.
68. Lee J.W., Kim Y.G., Soung Y.H., et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006, 25:1434-1436.
69. Malinge S., Ben-Abdelali R., Settegrana C., et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109:2202-2204.
70. Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
71. Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
72. Bousquet M., Quelen C., De Mas V., et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005, 24:7248-7252.
73. Xiang Z., Zhao Y., Mitaksov V., et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008, 111:4809-4812.
74. Jeong E.G., Kim M.S., Nam H.K., et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008, 14:3716-3721.
75. Flex E., Petrangeli V., Stella L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205:751-758.
76. Walters D.K., Mercher T., Gu T.L., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006, 10:65-75.
77. Kiyoi H., Yamaji S., Kojima S., Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007, 21:574-576.
78. Quintas-Cardama A., Cortes J.E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006, 81:973-988.
79. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
80. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
81. Deininger M.W., Vieira S., Mendiola R., et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000, 60:2049-2055.
82. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009, 27:619-628.
83. Harada Y., Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 2009, 220:16-20.
84. Appelbaum F.R., Kopecky K.J., Tallman M.S., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006, 135:165-173.
85. Arnould C., Phillipe C., Bourdon V., et al. The signal transducer and activator of transcription Stat5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic leukemia. Hum Mol Genet 1999, 8:1741-1749.
86. Wang L.C., Swat W., Fujiwara Y., et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998, 12:2392-2402.
87. Eguchi-Ishimae M., Eguchi M., Maki K., et al. Leukemia-related transcription factor TEL/ETV6 expands erythroid precursors and stimulates hemoglobin synthesis. Cancer Sci 2009, 100:689-697.
88. Bohlander S.K. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005, 15:162-174.
89. Tsuzuki S., Seto M., Greaves M., Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci USA 2004, 101:8443-8448.
90. Ford A.M., Palmi C., Bueno C., et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009, 119:826-836.
91. Schwaller J., Frantsve J., Aster J., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998, 17:5321-5333.
92. Onnebo S.M.N., Condron M.M., McPhee D.O., et al. Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion. Exp Hematol 2005, 33:182-188.
93. Kennedy J.A., Barabe F., Patterson B.J., et al. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci USA 2006, 103:16930-16935.
94. Buijs A., van Rompaey L., Molijn A.C., et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol 2000, 20:9281-9293.
95. Kawagoe H., Grosveld G.C. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Blood 2005, 106:4269-4277.
96. Million R.P., Aster J., Gilliland D.G., Van Etten R.A. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 2002, 99:4568-4577.
97. Million R.P., Harakawa N., Roumiantsev S., et al. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 2004, 24:4685-4695.
98. Slany R.K. The molecular biology of mixed lineage leukemia. Haematologica 2009, 94:984-993.
99. Chen C.Y., Tsay W., Tang J.L., et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 2003, 37:300-305.
100. Galm O., Yoshikawa H., Esteller M., et al. SOCS-1, a negative regulator of cytokine signalling, is frequently silenced in multiple myeloma. Blood 2003, 101:2784-2788.
101. Liu T.C., Lin S.F., Chang J.G., et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 2003, 123:654-661.
102. Monni R., Santos S.C., Mauchauffe M., et al. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells. Oncogene 2001, 20:849-858.
103. Fernandez-Mercado M., Cebrian V., Euba B., et al. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leuk Res 2008, 32:1638-1640.
104. Fourouclas N., Li J., Gilby D.C., et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008, 93:1635-1644.
105. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
106. Hait W.N., Hambley T.W. Targeted cancer therapeutics. Cancer Res 2009, 69:1263-1267.
107. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979.
108. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006, 312:1175-1178.
109. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002, 8:17-23.
110. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
111. Schindler T., Bornmann W., Pellicena P., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289:1938-1942.
112. Druker B.J. ST1571: a paradigm for clinical trials of molecularly targeted agents. Biomed Pharmacother 2001, 55:529-530.
113. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
114. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
115. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
116. Mauro M.J. Defining and managing imatinib resistance. Hematol Am Soc Hematol Educ Program 2006, 219-225.
117. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
118. Kantarjian H., Jabbour E., Grimley J., Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006, 5:717-718.
119. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
120. Schiffer C.A. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007, 357:258-265.
121. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30.
122. Meydan N., Grunberger T., Dadi H., et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
123. Miyamoto N., Sugita K., Goi K., et al. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 2001, 15:1758-1768.
124. Verstovsek S., Manshouri T., Quintas-Cardama A., et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 2008, 14:788-796.
125. Pardanani A., Hood J., Lasho T., et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007, 21:1658-1668.
126. Li Z., Xu M., Xing S., et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007, 282:3428-3432.
127. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414-9418.
128. Ikezoe T., Nishioka C., Tasaka T., et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006, 5:2522-2530.
129. Murata K., Kumagai H., Kawashima T., et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003, 278:32892-32898.
130. Fiedler W., Mesters R., Tinnefeld H., et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102:2763-2767.
131. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106:721-724.
132. Hexner E.O., Serdikoff C., Jan M., et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111:5663-5671.
133. Kelly L.M., Kutok J.L., Williams I.R., et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002, 99:8283-8288.
134. Zhou G.B., Zhang J., Wang Z.Y., et al. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc Lond B: Biol Sci 2007, 362:959-971.
135. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
136. Ellis L.M., Hicklin D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009, 15:7471-7478.
137. Xu Q., Simpson S.E., Scialla T.J., et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
138. Grandage V.L., Gale R.E., Linch D.C., Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005, 19:586-594.
139. Yilmaz O.H., Morrison S.J. The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells Mol Dis 2008, 41:73-76.
140. Martelli A.M., Evangelisti C., Chiarini F., et al. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Invest Drugs 2009, 18:1333-1349.
141. Plate J. Signals that maintain leukemic cell viability. Blood 2008, 112:1-2.
142. Prevo R., Deutsch E., Sampson O., et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008, 68:5915-5923.
143. Levy D.S., Kahana J.A., Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009, 113:1723-1729.
144. Lee J.T., McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002, 16:486-507.
145. Kyriakis J.M. Thinking outside the box about Ras. J Biol Chem 2009, 284:10993-10994.
146. Bardet V., Tamburini J., Ifrah N., et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 2006, 91:757-764.
147. Nishioka C., Ikezoe T., Yang J., et al. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res 2008, 32:865-872.
148. Wu J., Wong W.W., Khosravi F., et al. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004, 64:6461-6468.
149. Wojtkowiak J.W., Gibbs R.A., Mattingly R.R. Working together: farnesyl transferase inhibitors and statins block protein prenylation. Mol Cell Pharmacol 2009, 1:1-6.
150. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
151. Benekli M., Xia Z., Donohue K.A., et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Neoplasia 2002, 99:252-257.
152. Ward A.C., Touw I., Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000, 95:19-29.
153. Sternberg D.W., Gilliland D.G. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol 2004, 22:361-371.
154. Lewis R.S., Ward A.C. Stat5 as a marker of leukemia. Expert Rev Mol Diag 2008, 8:73-82.
155. Shuai K., Halpern J., ten Hoeve J., et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13:247-254.
156. Dong S., Tweardy D.J. Interactions of STAT5b-RARα, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002, 99:2637-2646.
157. Choudhary C., Brandts C., Schwable J., et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007, 110:370-374.
158. Migone T.-S., Lin J.-X., Cereseto A., et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995, 269:79-81.
159. Silver D.L., Naora H., Liu J., et al. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004, 64:3550-3558.
160. Tomita M., Kawakami H., Uchihara J.N., et al. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology 2006, 3:22.
161. Catlett-Falcone R., Landowski T.H., Oshiro M.M., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
162. Gesbert F., Griffin J.D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000, 96:2269-2276.
163. Moore M.A., Dorn D.C., Schuringa J.J., et al. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol 2007, 35:105-116.
164. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004, 8:409-422.
165. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
166. Scherr M., Chaturvedi A., Battmer K., et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 2006, 107:3279-3287.
167. Turkson J., Ryan D., Kim J.S., et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation and cell transformation. J Biol Chem 2001, 276:45443-45455.
168. Ren Z., Cabell L.A., Schaefer T.S., McMurray J.S. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett 2003, 13:633-636.
169. Chien C.M., Yang S.H., Lin K.L., et al. Novel indoloquinoline derivative, IQDMA, suppresses STAT5 phosphorylation and induces apoptosis in HL-60 cells. Chem Biol Interact 2008, 176:40-47.
170. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15:3958-3969.
171. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009, 15:3970-3977.
172. Fantin V.R., Loboda A., Paweletz C.P., et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008, 68:3785-3794.
173. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408-1413.
174. Yanada M., Ohno R., Naoe T. Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 2009, 89:3-13.
175. Brown P., Levis M., McIntyre E., et al. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 2006, 20:1368-1376.
176. Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004, 101:3130-3135.
177. Roboz G.J., Giles F.J., List A.F., et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006, 20:952-957.
178. El Kinge A.R., Hatoum H.A., Mahfouz R.A., et al. Gemtuzumab ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res 2009, 33:565-566.
179. Gasparini G., Longo R., Torino F., et al. Is tailored therapy feasible in oncology?. Crit Rev Oncol Hematol 2006, 57:79-101.